Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

FairJourney Biologics S.A., global leader in antibody discovery and development, today announced the formation of its Supervisory Board to support the Company's ongoing strategy for growth and ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to ...

This Perspective article examines the interplay between antibody diversification mechanisms and highlights the importance of constant regions in influencing the specificity and functionality of ...

After spending years unsuccessfully attempting to develop a Covid-19 vaccine, Inovio is now reporting promising results from early testing of an experimental Covid treatment.